VIRGINIA RETIREMENT SYSTEMS ET Al Cuts Stock Position in Medpace Holdings, Inc. $MEDP

VIRGINIA RETIREMENT SYSTEMS ET Al lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,439 shares of the company’s stock after selling 1,620 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Medpace were worth $2,797,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Employees Retirement System of Texas bought a new position in Medpace in the 2nd quarter worth about $36,000. IFP Advisors Inc grew its position in Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the last quarter. Hantz Financial Services Inc. increased its stake in Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after purchasing an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in Medpace by 514.3% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after buying an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This represents a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the transaction, the chief executive officer owned 646,184 shares in the company, valued at $381,694,426.96. This trade represents a 0.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 387,925 shares of company stock worth $233,386,647 in the last three months. 20.30% of the stock is currently owned by company insiders.

Medpace Trading Down 1.3%

Shares of MEDP opened at $561.65 on Friday. The firm has a market cap of $15.82 billion, a PE ratio of 39.28, a P/E/G ratio of 2.12 and a beta of 1.43. The firm has a fifty day simple moving average of $580.19 and a two-hundred day simple moving average of $487.47. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same period last year, the business posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Mizuho upped their target price on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research note on Friday, October 24th. TD Cowen upped their price objective on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research report on Friday, October 24th. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Finally, Truist Financial set a $555.00 price target on Medpace in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $490.82.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.